TABLE 1.
Demographic and clinical characteristics of patientsa
| Characteristic | Value for treatment group |
||
|---|---|---|---|
| LAMB | ABCD | ABLC | |
| Total subjects | 11 | 28 | 5 |
| Mean age in yr | 46 ± 4 | 50 ± 3 | 55 ± 5 |
| Sex | |||
| Male | 9 | 14 | 4 |
| Female | 2 | 14 | 1 |
| Mean wt (kg) | 68 ± 4 | 63 ± 2 | 71 ± 8 |
| Main diagnosis | |||
| Hematological disorder | 6 | 18 | 2 |
| Acute myeloid leukemia | 2 | 3 | |
| Other hem. malignancy | 2 | 8 | 2 |
| Lymphoma | 2 | 7 | |
| Solid-organ transplantation | 2 | 4 | 1 |
| Liver | 2 | 3 | |
| Heart | 1 | ||
| Kidney | 1 | ||
| Solid tumor | 2 | 1 | 1 |
| Carcinoma of lung | 1 | ||
| Brain tumor | 1 | ||
| Skin tumor | 1 | ||
| Pharynx cancer | 1 | ||
| Liver cirrhosis | 4 | 1 | |
| Other | 2 | 1 | |
| Laboratory values | |||
| Creatinine (mg/dl) | 0.94 ± 0.10 | 1.33 ± 0.17 | 1.06 ± 0.37 |
| Bilirubin (mg/dl) | 6.51 ± 2.81 | 10.56 ± 2.56 | 11.65 ± 6.26 |
| Prothrombin time (%) | 76 ± 7 | 62 ± 4 | 73 ± 10 |
| AMB treatment | |||
| Duration (days) | 6.1 ± 0.9 | 8.8 ± 1.5 | 5.6 ± 2.7 |
| Daily dose (mg) | 309 ± 22 | 279 ± 16 | 300 ± 47 |
| Daily dose (mg/kg) | 4.55 ± 0.23 | 4.46 ± 0.19 | 4.25 ± 0.58 |
| Cumulative dose (mg) | 1,688 ± 285 | 2,176 ± 340 | 2,061 ± 1,259 |
| Time from start of last infusion to sampling (h) | 22.0 ± 12.7 | 12.6 ± 2.5 | 7.3 ± 3.1 |
a
Means ± standard errors of the means. Creatinine, plasma creatinine; normal range, 0.70 to 1.20 mg/dl. Bilirubin, plasma bilirubin; normal range, 0.00 to 1.28 mg/dl. Prothrombin time, normal range, 70 to 130 %. Duration, duration of treatment with lipid-formulated AMB. The time from start of last infusion to sampling was variable, since BALs were scheduled according to clinical requirements. The infusion time was 4 h. When AMB treatment was started at the intensive care unit, the choice of AMB formulation was made by randomization. In patients already on AMB at admission, the respective therapy was continued. Hem., hematological.